Gastrointestinal Cancer

The iFOBT test examines the stool for hidden blood, which could come from anywhere in the GI tract, and possibly indicates a colon tumor or precancerous growths known as polyps.

A greater number of lymph nodes are being screened in colon cancer but this has not led to more diagnoses of node-positive colon cancer.

The following is a roundup of TPS abstracts that feature trials open to patients aged >17 years with a broad range of cancer types.

Three new genetic mutations have been identified in patients with Barrett's esophagus (BE) and esophageal adenocarcinoma (EAC).

Adding oxaliplatin to 5-fluorouracil before and after surgery for the treatment of locally advanced rectal cancer is demonstrating significant benefit.

A panel voted 9-6 advising the FDA not to approve dapagliflozin, a diabetes drug that forces the body to dump sugar.

The field of immunotherapy is brimming with questions that researchers are working to answer, and many of those efforts were on display at the ASCO annual meeting.

Almost 1 in 3 adults in the United States do not get screened regularly.

Dr. Heikki Joensuu from the Helsinki University Central Hospital Discusses Resistance to Imatinib in GIST

A recent study showed that a patient-navigation-based intervention may help increase the rate of CRC screening in typically underserved groups, including low-income, ethnically diverse patients.

Dr. Howard Scher form Memorial Sloan-Kettering Cancer Center Discusses Circulating Tumor Cells

FDA digest from June discussing warning labels, pancreatic treatment choices, and the quest for a lymphoma drug.

A vast majority of Medicare patients with cancer are receiving appropriate surgical care that is in line with current treatment guidelines.

Dr. Nicholas Vogelzang from the Comprehensive Cancer Centers of Nevada Describes Cabozantinib's side effects

Investigators in a large cohort study reported that heavy alcohol consumption, particularly beer, significantly increases the risk of gastric cancer.

Dr. Kris From Memorial Sloan-Kettering Cancer Center Discusses the Imatinib GIST Clinical Trial

Primary cancers of the lung, esophagus, and pancreas-all of which have a poor prognosis-account for >35% of all cancer deaths in the United States annually

Dr. Heikki Joensuu from the Helsinki University Central Hospital Discusses the Progress of gastrointestinal stromal tumors (GIST) Treatments

3 years of treatment with imatinib (Gleevec) after surgery in patients with high-risk GIST improved overall and recurrence-free survival

Dr. Heikki Joensuu from the Helsinki University Central Hospital Summarizes the Imatinib for High-Risk high-risk gastrointestinal stromal tumors (GIST) Trial

Janet Hampton from the University of Michigan Health System Cancer Center Explains the Distress Thermometer Study

Janet Hampton University of Michigan Health System Cancer Center Explains Distress Thermometer Study Results

The FDA has approved Sutent (sunitinib) for the treatment of patients with unresectable, locally advanced, or metastatic pancreatic neuroendocrine tumors (pNET)

Janet Hampton Describes the Distress Thermometer

Results from a phase III study showed that the chemotherapy combination FOLFIRINOX nearly doubled the survival time for patients with pancreatic adenocarcinoma